Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 7 studies | 27% ± 9% | |
enterocyte | 4 studies | 19% ± 2% | |
basal cell | 3 studies | 26% ± 2% |
Insufficient scRNA-seq data for expression of CBLC at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 98% | 873.38 | 322 / 328 | 95% | 96.64 | 169 / 178 |
prostate | 87% | 960.17 | 212 / 245 | 95% | 77.69 | 477 / 502 |
liver | 100% | 837.57 | 226 / 226 | 74% | 31.39 | 300 / 406 |
stomach | 73% | 703.64 | 262 / 359 | 97% | 110.49 | 278 / 286 |
intestine | 47% | 1120.80 | 456 / 966 | 98% | 124.12 | 518 / 527 |
breast | 56% | 445.07 | 255 / 459 | 88% | 45.78 | 980 / 1118 |
bladder | 48% | 547.52 | 10 / 21 | 93% | 118.17 | 469 / 504 |
esophagus | 38% | 967.96 | 555 / 1445 | 98% | 106.30 | 179 / 183 |
kidney | 89% | 419.06 | 79 / 89 | 14% | 3.24 | 128 / 901 |
lung | 11% | 38.40 | 64 / 578 | 90% | 65.66 | 1040 / 1155 |
ureter | 0% | 0 | 0 / 0 | 100% | 156.78 | 1 / 1 |
tonsil | 0% | 0 | 0 / 0 | 96% | 124.58 | 43 / 45 |
ovary | 0% | 0 | 0 / 180 | 94% | 65.41 | 403 / 430 |
uterus | 6% | 45.92 | 11 / 170 | 85% | 91.53 | 388 / 459 |
skin | 72% | 2016.18 | 1305 / 1809 | 5% | 2.08 | 23 / 472 |
thymus | 10% | 30.98 | 66 / 653 | 2% | 0.94 | 12 / 605 |
adrenal gland | 0% | 0 | 0 / 258 | 0% | 0.10 | 1 / 230 |
adipose | 0% | 2.56 | 5 / 1204 | 0% | 0 | 0 / 0 |
spleen | 0% | 0.98 | 1 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 2.28 | 2 / 929 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.60 | 1 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 1.00 | 1 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
brain | 0% | 0 | 0 / 2642 | 0% | 0 | 0 / 705 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
heart | 0% | 0 | 0 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0042059 | Biological process | negative regulation of epidermal growth factor receptor signaling pathway |
GO_0007165 | Biological process | signal transduction |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0050821 | Biological process | protein stabilization |
GO_1990790 | Biological process | response to glial cell derived neurotrophic factor |
GO_0043407 | Biological process | negative regulation of MAP kinase activity |
GO_0007175 | Biological process | negative regulation of epidermal growth factor-activated receptor activity |
GO_0043524 | Biological process | negative regulation of neuron apoptotic process |
GO_0005886 | Cellular component | plasma membrane |
GO_0045121 | Cellular component | membrane raft |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0005154 | Molecular function | epidermal growth factor receptor binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0005509 | Molecular function | calcium ion binding |
GO_0005515 | Molecular function | protein binding |
GO_0001784 | Molecular function | phosphotyrosine residue binding |
GO_0030971 | Molecular function | receptor tyrosine kinase binding |
GO_0017124 | Molecular function | SH3 domain binding |
Gene name | CBLC |
Protein name | E3 ubiquitin-protein ligase CBL (EC 2.3.2.27) E3 ubiquitin-protein ligase CBL-C (EC 2.3.2.27) (RING finger protein 57) (RING-type E3 ubiquitin transferase CBL-C) (SH3-binding protein CBL-3) (SH3-binding protein CBL-C) (Signal transduction protein CBL-C) |
Synonyms | RNF57 CBL3 |
Description | FUNCTION: Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Functionally coupled with the E2 ubiquitin-protein ligases UB2D1, UB2D2 and UB2D3. Regulator of EGFR mediated signal transduction; upon EGF activation, ubiquitinates EGFR. Isoform 1, but not isoform 2, inhibits EGF stimulated MAPK1 activation. Promotes ubiquitination of SRC phosphorylated at 'Tyr-419'. In collaboration with CD2AP may act as regulatory checkpoint for Ret signaling by modulating the rate of RET degradation after ligand activation; CD2AP converts it from an inhibitor to a promoter of RET degradation; the function limits the potency of GDNF on neuronal survival. . FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. . |
Accessions | ENST00000341505.4 [Q9ULV8-2] Q9ULV8 A0A2R8Y647 ENST00000647063.1 ENST00000647358.2 [Q9ULV8-1] |